SEC Form 4 · accession 0001562180-15-000431
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Albert Robichaud
Officer — Chief Scientific Officer
Period of report
Jun 1, 2015
Accepted (ET)
Jun 2, 2015 · 6:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 1, 2015 | S | 4,945 | $73.8935 | D | 221,277 | D | |
| Common StockF3 | Jun 1, 2015 | S | 5,624 | $72.9341 | D | 215,653 | D | |
| Common StockF4 | Jun 1, 2015 | S | 5,231 | $71.6706 | D | 210,422 | D | |
| Common StockF5 | Jun 1, 2015 | S | 200 | $71.205 | D | 210,222 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2This transaction was executed in multiple trades at prices ranging from $73.42 USD to $74.42 USD. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices ranging from $72.47 USD to $73.40 USD. The price reported above reflects the weighted average sale price.
- F4This transaction was executed in multiple trades at prices ranging from $71.28 USD to $72.24 USD. The price reported above reflects the weighted average sale price.
- F5This transaction was executed in multiple trades at prices ranging from $71.20 USD to $71.21 USD. The price reported above reflects the weighted average sale price.